Everolimus
Generic Name: everolimus
Brand Names:
Everolimus
Everolimus is a macrolide immunosuppressant available as tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths for organ rejection prophylaxis.
Overview
Everolimus is a macrolide immunosuppressant available as tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg strengths for organ rejection prophylaxis.
Uses
Indicated for organ rejection prophylaxis in adult transplant recipients. Use in kidney transplant at low-moderate immunologic risk and in liver transplant 30 or more days post-transplant.
Dosage
Kidney transplant: Initial dose 0.75 mg orally twice daily. Liver transplant: Initial dose 1 mg orally twice daily, starting 30 or more days post-transplant. Adjust dose based on trough concentrations (target 3-8 ng/mL). Reduce initial dose for hepatic impairment.
Side Effects
Common reactions in kidney transplant (20% or greater): peripheral edema, constipation, hypertension, nausea, anemia, urinary tract infection, hyperlipidemia. In liver transplant (greater than 10%): diarrhea, headache, peripheral edema, hypertension, nausea, pyrexia.
Interactions
Strong CYP3A4 inhibitors (ketoconazole, cyclosporine, erythromycin) and inducers (rifampin) affect levels. Grapefruit juice should be avoided. Cannabidiol may increase everolimus levels.
Warnings
WARNING: MALIGNANCIES and SERIOUS INFECTIONS; KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY; and MORTALITY IN HEART TRANSPLANTATION. Only experienced physicians should prescribe. Increased risk of infections, malignancies, kidney graft thrombosis, nephrotoxicity with cyclosporine. Contraindicated with hypersensitivity to everolimus or sirolimus.
Pregnancy
Based on animal studies and mechanism of action, everolimus can cause fetal harm. Advise females of reproductive potential to use effective contraception during and 8 weeks after treatment. Not recommended during breastfeeding.
Frequently Asked Questions
What is Everolimus used for?▼
Indicated for organ rejection prophylaxis in adult transplant recipients. Use in kidney transplant at low-moderate immunologic risk and in liver transplant 30 or more days post-transplant.
What are the side effects of Everolimus?▼
Common reactions in kidney transplant (20% or greater): peripheral edema, constipation, hypertension, nausea, anemia, urinary tract infection, hyperlipidemia. In liver transplant (greater than 10%): diarrhea, headache, peripheral edema, hypertension, nausea, pyrexia.
Can I take Everolimus during pregnancy?▼
Based on animal studies and mechanism of action, everolimus can cause fetal harm. Advise females of reproductive potential to use effective contraception during and 8 weeks after treatment. Not recommended during breastfeeding.
What are the important warnings for Everolimus?▼
WARNING: MALIGNANCIES and SERIOUS INFECTIONS; KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY; and MORTALITY IN HEART TRANSPLANTATION. Only experienced physicians should prescribe. Increased risk of infections, malignancies, kidney graft thrombosis, nephrotoxicity with cyclosporine. Contraindicated with hypersensitivity to everolimus or sirolimus.
Related Medications
Dabrafenib
dabrafenib
11 DESCRIPTION Dabrafenib mesylate is a kinase inhibitor. The chemical name for dabrafenib mesylate is N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene sulfonamide, methanesulfonate salt. It has the molecular formula C 23 H 20 F 3 N 5 O 2 S 2 •CH 4 O 3 S and a molecular weight of 615.68 g/mol.
Daratumumab And Hyaluronidase-fihj (human Recombinant)
daratumumab and hyaluronidase-fihj (human recombinant)
CD38-directed Cytolytic Antibody [EPC]
11 DESCRIPTION Daratumumab is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody that binds to the CD38 antigen. Daratumumab is produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology. The molecular weight of daratumumab is approximately 148 kDa. Hyaluronidase (recombinant human) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously.
Nafcillin
nafcillin
DESCRIPTION Nafcillin Injection, USP is a sterile injectable product containing nafcillin which is added as Nafcillin Sodium, USP, a semisynthetic penicillin derived from the penicillin nucleus, 6-aminopenicillanic acid. The chemical name of nafcillin sodium is Monosodium (2 S ,5 R ,6 R )-6-(2-ethoxy-1-naphthamido)-3,3-dimethyl-7-oxo-4-thia-1- azabicyclo[3.2.0]heptane-2-carboxylate monohydrate. It is resistant to inactivation by the enzyme penicillinase (beta-lactamase).
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.